Treatment for Relapsed/Refractory Acute Myeloid Leukemia

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Relapsed or refractory acute myeloid leukemia (r/r AML) presents a significant clinical challenge with poor prognosis.
• Allogeneic hematopoietic stem cell transplantation (HSCT) is the primary curative option, necessitating effective salvage therapy to achieve remission pre-transplant.

Purpose of the Study:

• To review current treatment strategies for r/r AML, focusing on salvage therapies and the emerging role of targeted agents.
• To highlight recent advancements in novel therapies for specific molecular subsets of r/r AML.

Main Methods:

• Review of current literature on salvage chemotherapy regimens, including anthracycline and high-dose cytarabine.
• Analysis of data on targeted therapies approved for specific mutations, such as FLT3 and IDH1/2.
• Discussion of ongoing investigations into novel agents and combination strategies.

Main Results:

• Gilteritinib demonstrates superior efficacy in FLT3-mutated r/r AML compared to intensive salvage regimens, with FDA and EMA approval.
• Ivosidenib and enasidenib are approved by the FDA for IDH1/2-mutated r/r AML.
• Emerging agents targeting TP53, CD47, and other pathways show promising early results.

Conclusions:

• Targeted therapies are transforming the treatment landscape for molecularly defined r/r AML.
• Further research is crucial to optimize the combination of novel agents with each other and with conventional chemotherapy.